We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Bioactive Phosphate Glasses Eradicate Nosocomial Bacteria

By HospiMedica International staff writers
Posted on 15 Apr 2019
A new study describes how degradable bioactive phosphate glasses could be used as an antimicrobial delivery system, releasing biologically significant ions in a controlled manner.

Researchers at Aston University (Birmingham, United Kingdom), the University of Birmingham (UB; United Kingdom), and other institutions used a centuries-old glass staining technique to lace glace with varying concentrations of cobalt, which are then ground to a fine powder. More...
The bioactive glasses provide a controlled release of antimicrobial ions as they dissolve; at the highest concentration, the glass completely eradicated E. coli in a Petri dish in six hours, C. albicans within 24 hours, and S. aureus levels were reduced by 99% after 24 hours.

The cobalt oxide ions cause strong, time dependent, and strain specific antimicrobial activity of the glasses against microorganisms when in direct contact, causing bacterial cell wall membranes to burst. The metallic ions also leach out of the glass, killing bacteria not in direct contact, but to a lesser degree. In other studies, similar anti-bacterial qualities have been observed in bioactive glasses laced with other metals, including copper, zinc, and silver. The study was published in the January 2019 issue of ACS Biomaterials Science and Engineering.

“With the rise of antimicrobial resistance, these glasses have the potential to radically transform how we guard against common hospital infections, because if we can stop the bacteria from multiplying it negates the need for heavy doses of antibiotics,” said senior author Richard Martin, PhD, of Aston University. “This would be good news for patients, who would be at a much-reduced risk of contracting a potentially life-threatening infection during a hospital stay, but also good for healthcare systems, which could make more judicious use of antibiotics and prevent costly unplanned hospital stays.”

Hospital acquired infections (HAIs) are defined as those occurring 48 hours after admission, within three days of discharge, or within 30 days of surgery. They can be caused by organisms lurking on the bodies or clothing of healthcare workers and on hospital surfaces such as doorknobs, curtains, and furniture. Resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), erythromycin-resistant Enterococcus, and carbapenem-resistant Enterobacteriaceae acerbate the problem.

Related Links:
Aston University
University of Birmingham


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
New
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.